Skip to main content

Osimertinib and Abemaciclib for the Treatment of Stage IV or Recurrent Non-small Cell Lung Cancer with EGFR Activating Mutations with Osimertinib Resistance

Trial Status: Active

This phase II trial studies the effect of osimertinib and abemaciclib in treating patients with stage IV non-small cell lung cancer or non-small cell lung cancer that has come back (recurrent) and who have EGFR activating mutations resistant to osimertinib. Osimertinib and abemaciclib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth.

Inclusion Criteria

  • Histologically or cytologically confirmed non-small cell lung cancer (NSCLC)-lung adenocarcinoma histology
  • Tumor must harbor an EGFR activating mutation (exon 21 L858R, exon 19 deletion, exon 18 G719X, exon 21 L861Q)
  • Patient must have stage IV, recurrent or metastatic disease with EGFR mutant disease
  • Patient must have progressive disease on or after osimertinib (any number of prior treatment is allowed)
  • At least one measurable lesion according to Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1
  • Age > 18 years
  • Eastern Cooperative Oncology Group (ECOG) performance status =< 1
  • Patients who received chemotherapy must have recovered (Common Terminology Criteria for Adverse Events [CTCAE] grade =< 1) from the acute effects of chemotherapy except for residual alopecia or grade 2 peripheral neuropathy prior to randomization. A washout period of at least 21 days is required between last chemotherapy dose and randomization (provided the patient did not receive radiotherapy)
  • Patients who received adjuvant radiotherapy must have completed and fully recovered from the acute effects of radiotherapy. A washout period of at least 14 days is required between end of radiotherapy and randomization
  • Absolute neutrophil count (ANC) >= 1.5 x 10^9/L
  • Platelets >= 100 x 10^9/L
  • Hemoglobin >= 8 g/dL * Patients may receive erythrocyte transfusions to achieve this hemoglobin level at the discretion of the investigator. Initial treatment must not begin earlier than the day after the erythrocyte transfusion
  • Total bilirubin =< 1.5 x upper limit of normal (ULN) * Patients with Gilbert’s syndrome with a total bilirubin =< 2.0 times ULN and direct bilirubin within normal limits are permitted
  • Alanine aminotransferase (ALT) and aspartate aminotransferase (AST) =< 3 x ULN
  • Serum creatinine =< 1.5 x ULN
  • Written informed consent that is consistent with International Conference on Harmonization (ICH)-Good Clinical Practice (GCP) guidelines. Ability to understand and sign consent to be provided by University of California San Diego (UCSD) Institutional Review Board (IRB)
  • Negative urinary pregnancy test within 7 days prior to entry of study
  • Men and women of child bearing age must agree to contraception methods prior to entry of study and continue on that for 3 months for women and 6 months for men after last dose of osimertinib (details will be submitted in actual protocol) and notification of principal investigator (PI) if pregnancy occurs
  • Patients with brain metastases may enroll in this study providing they have been treated and remain asymptomatic
  • The patient is able to swallow oral medications

Exclusion Criteria

  • Chemotherapy or other investigational agent within three weeks prior to the start of study treatment
  • Radiotherapy within 4 weeks prior to randomization, except as follows: * Palliative radiation to target organs other than chest or stereotactic radiotherapy to the chest may be allowed up to 2 weeks prior to treatment with osimertinib and abemaciclib * Single dose palliative treatment for symptomatic metastasis outside above allowance to be discussed with sponsor prior to enrolling
  • Major surgery within 4 weeks before starting study treatment or scheduled for surgery during the projected course of the study
  • Known hypersensitivity to osimertinib or the excipients of any of the trial drugs
  • History or presence of clinically relevant cardiovascular abnormalities such as uncontrolled hypertension, congestive heart failure New York Heart Association (NYHA) classification of 3, unstable angina or poorly controlled arrhythmia as determined by the investigator. Myocardial infarction within 6 months prior to study enrollment
  • Women of child-bearing potential (WOCBP) and men who are able to father a child, unwilling to be abstinent or use adequate contraception prior to study entry, for the duration of study participation and for at least 28 days after treatment has ended * Note: for osimertinib this must be 28 days, however this may be longer for other drugs in
  • Female patients of childbearing potential who are nursing or are pregnant or are not using an acceptable method of birth control, or do not plan to continue using this method throughout the study and/or do not agree to submit to pregnancy testing required by this protocol
  • Previous or concomitant malignancies at other sites, except effectively treated non-melanoma skin cancers, carcinoma in situ of the cervix, ductal carcinoma in situ or effectively treated malignancy that has been in remission for more than 3 years and is considered to be cured
  • Requiring treatment with any of the prohibited concomitant medications (potent P-glycoprotein inducers and inhibitors)
  • Known pre-existing interstitial lung disease (patients with previous radiation induced interstitial lung disease are allowed provided they do not require active treatment and symptoms attributed to interstitial lung disease have resolved)
  • Any history or presence of poorly controlled gastrointestinal disorders that could affect the absorption of osimertinib (e.g. Crohn’s disease, ulcerative colitis, chronic diarrhea, and malabsorption)
  • Active hepatitis B infection (defined as presence of hepatitis B surface antigen [HepB sAg] and/ or Hep B DNA), active hepatitis C infection (defined as presence of hepatitis C [Hep C] ribonucleic acid [RNA]) and/or known human immunodeficiency virus (HIV) carrier
  • Fridericia's correction formula (QTcF) > 470 ms on average of 3 electrocardiogram (ECG) recordings
  • Leptomeningeal carcinomatosis
  • Patients with controlled central nervous system (CNS) metastases are allowed. Radiotherapy or surgery for CNS metastases must have been completed > 2 weeks prior to study entry. Patients must be neurologically stable, having no new neurologic deficits on clinical examination, and no new findings on CNS imaging. Steroid use for management of CNS metastases must be at a stable dose for two weeks preceding study entry.
  • The patient has serious preexisting medical condition(s) that would preclude participation in this study (for example, interstitial lung disease, severe dyspnea at rest or requiring oxygen therapy, history of major surgical resection involving the stomach or small bowel, or preexisting Crohn’s disease or ulcerative colitis or a preexisting chronic condition resulting in baseline grade 2 or higher diarrhea)
  • The patient has active bacterial infection (requiring intravenous [IV] antibiotics at time of initiating study treatment), fungal infection, or detectable viral infection (such as known human immunodeficiency virus positivity or with known active hepatitis B or C [for example, hepatitis B surface antigen positive]. Screening is not required for enrollment
  • The patient has a personal history of any of the following conditions: syncope of cardiovascular etiology, ventricular arrhythmia of pathological origin (including, but not limited to, ventricular tachycardia and ventricular fibrillation), or sudden cardiac arrest
  • Clinically active interstitial lung disease, radiation pneumonitis requiring steroid treatment and further entry to be determined on an individual basis
  • Use of medications or supplements known to be major inducers of CYP3A4
  • Comorbidities not limited to unstable angina, congestive heart failure; electrocardiogram (EKG) abnormalities including but not limited to QT prolongation; gastrointestinal diseases limiting absorption of oral medications; psychiatric illnesses and other social situations which may limit participation and compliance on the study
  • Prior CDK4/6 inhibitor treatment is prohibited


San Diego
University of California San Diego
Status: ACTIVE
Contact: Hatim Husain
Phone: 858-534-1590


I. To determine the rate of progression free survival at 6 months (PFS6m) on the combination.


I. To determine the response rate of the combination.

II. To examine the adverse events and serious adverse events of the combination.

III. To examine the progression-free survival and overall survival of the combination and duration of response.

IV. To explore the mechanism of resistance to osimertinib and subsequent treatment with osimertinib and abemaciclib and correlate with clinical benefit to osimertinib and abemaciclib.

V. To explore pertinent plasma deoxyribonucleic acid (DNA) markers of EGFR and resistance mechanisms of EGFR-TKIs and correlate with benefit to the combination

VI. To examine the response rate in patients with cell cycle gene aberrations.


Patients receive abemaciclib orally (PO) twice daily (BID) and osimertinib PO once daily (QD) on days 1-28. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity.

After completion of study treatment, patients are followed up for 100 weeks.

Trial Phase Phase II

Trial Type Treatment

Lead Organization
University of California San Diego

Principal Investigator
Hatim Husain

  • Primary ID 190752
  • Secondary IDs NCI-2020-14097
  • ID NCT04545710